BACKGROUND: To clarify the clinicopathological features of breast cancer in young females, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed. METHODS: The clinicopathological characteristics were compared between young (<35) patients and non-young (≥35) patients among 109,617 records registered between 2004 and 2009. RESULTS: The numbers of young and non-young patients were 2,982 (2.7 %) and 106,295 (97.0 %), respectively. The young patients had more cases of a familial history of breast cancer, more subjective symptoms, fewer bilateral tumors, lower BMIs, larger tumors, more positive lymph nodes, fewer instances of an ER-positive status, more instances of an HER2-positive status, more triple-negative tumors and more advanced TNM stages. The young patients more frequently received neoadjuvant chemotherapy and breast-conserving therapy (BCT) compared with the non-young patients. Eighty percent of all patients received adjuvant therapy. The young patients were more frequently treated with chemotherapy, molecular targeted therapy and radiation therapy than the non-young patients. CONCLUSIONS: In this study, young patients with breast cancer were diagnosed at more advanced stages and had more endocrine-unresponsive tumors than non-young patients. Further prognostic analyses should be conducted in this cohort.
BACKGROUND: To clarify the clinicopathological features of breast cancer in young females, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed. METHODS: The clinicopathological characteristics were compared between young (<35) patients and non-young (≥35) patients among 109,617 records registered between 2004 and 2009. RESULTS: The numbers of young and non-young patients were 2,982 (2.7 %) and 106,295 (97.0 %), respectively. The young patients had more cases of a familial history of breast cancer, more subjective symptoms, fewer bilateral tumors, lower BMIs, larger tumors, more positive lymph nodes, fewer instances of an ER-positive status, more instances of an HER2-positive status, more triple-negative tumors and more advanced TNM stages. The young patients more frequently received neoadjuvant chemotherapy and breast-conserving therapy (BCT) compared with the non-young patients. Eighty percent of all patients received adjuvant therapy. The young patients were more frequently treated with chemotherapy, molecular targeted therapy and radiation therapy than the non-young patients. CONCLUSIONS: In this study, young patients with breast cancer were diagnosed at more advanced stages and had more endocrine-unresponsive tumors than non-young patients. Further prognostic analyses should be conducted in this cohort.
Authors: K Kyono; T Hashimoto; M Toya; M Koizumi; C Sasaki; S Shibasaki; N Aono; Y Nakamura; R Obata; N Okuyama; Y Ogura; H Igarashi Journal: J Assist Reprod Genet Date: 2017-09-02 Impact factor: 3.412
Authors: Winnie Yeo; Hang-Mei Lee; Amy Chan; Emily Yy Chan; Miranda Cm Chan; Keeng-Wai Chan; Sharon Ww Chan; Foon-Yiu Cheung; Polly Sy Cheung; Peter Hk Choi; Josette Sy Chor; William Wl Foo; Wing-Hong Kwan; Stephen Ck Law; Lawrence Pk Li; Janice Wh Tsang; Yuk Tung; Lorna Ls Wong; Ting-Ting Wong; Chun-Chung Yau; Tsz-Kok Yau; Benny Cy Zee Journal: World J Clin Oncol Date: 2014-12-10
Authors: Omar Farouk; Mohamed A Ebrahim; Ahmad Senbel; Ziad Emarah; Waleed Abozeed; Mohamed O Seisa; Summer Mackisack; Salah Abdel Jalil; Safaa Abdelhady Journal: Breast Cancer (Dove Med Press) Date: 2016-04-05